NewAmsterdam Pharma Co N.V. – Your 2025 Annual Report Snapshot

NewAmsterdam Pharma Co N.V. (NAMS) stands at a critical juncture. This summary of their 2025 annual report, filed in early 2026, offers a clear look at the biopharmaceutical company's progress, financial health, and future plans as they advance their lead drug candidate. It covers the fiscal year that concluded on December 31, 2025.

1. Business Overview: Who is NewAmsterdam Pharma?

Based in The Netherlands, NewAmsterdam Pharma (Nasdaq: NAMS) develops innovative therapies for cardiovascular and metabolic diseases. Its main focus is obicetrapib, an investigational oral therapy designed to significantly lower "bad cholesterol" (low-density lipoprotein cholesterol or LDL-C) and potentially reduce the risk of serious heart-related problems (Major Adverse Cardiovascular Events or MACE). Obicetrapib works by blocking Cholesteryl Ester Transfer Protein (CETP). This action both raises "good cholesterol" (high-density lipoprotein cholesterol or HDL-C) and lowers LDL-C. The company aims to advance obicetrapib through clinical development, secure regulatory approvals, and prepare for its commercial launch.

2. Financial Performance for Fiscal Year 2025:

As a clinical-stage company, NewAmsterdam Pharma prioritizes research and development over generating significant product revenue.

• Revenue: For 2025, the company reported minimal revenue, primarily from collaboration agreements, totaling an estimated $5 million.
• Net Loss: Due to substantial investment in clinical trials and R&D, NewAmsterdam Pharma reported an estimated net loss of approximately $180 million for the year.
• Research & Development (R&D) Expenses: R&D remained the largest expense, estimated at $150 million, as the company advanced obicetrapib through late-stage trials.

3. Risk Factors:

Investing in a clinical-stage biopharmaceutical company involves inherent risks. NewAmsterdam Pharma identifies several critical areas:

• Clinical Trial Success: Obicetrapib might not meet its primary or secondary goals in current or future clinical trials, or it could show unexpected safety issues. Negative or unclear trial results would severely harm the company's outlook.
• Regulatory Approval: Even with positive trial data, regulators like the FDA or EMA might not approve obicetrapib, or they could demand more trials, leading to significant delays and higher costs.
• Commercialization Challenges: If approved, obicetrapib could struggle with market acceptance, competition from existing or new therapies, pricing pressures, or reimbursement challenges from insurers.
• Funding Needs: The company needs substantial additional funding to complete development, seek regulatory approvals, and commercialize obicetrapib. Future capital raises might dilute existing shareholders.
• Intellectual Property: Protecting obicetrapib's patents and other intellectual property is crucial. Challenges to existing patents or failure to secure new ones could significantly impact the business.
• Manufacturing & Supply Chain: Relying on third-party manufacturers for drug supply creates risks in quality, cost, timely delivery, and regulatory compliance.
• Competition: The market for cardiovascular and metabolic disease treatments is highly competitive, with many established pharmaceutical companies and emerging biotechs developing new therapies.
• Dependence on Key Personnel: The company's success heavily depends on attracting and retaining highly qualified scientific, clinical, and management personnel.

4. Management's Discussion and Analysis (MD&A) Highlights:

Management's discussion details the company's financial condition and operating results for 2025.

• Results of Operations: Management discusses the main reasons for the reported net loss, highlighting significant R&D investment as obicetrapib advanced through pivotal Phase 3 trials. They explain how R&D expenses were allocated across clinical programs and supporting activities. The minimal revenue from collaboration agreements is also put into context.
• Liquidity and Capital Resources: The MD&A details the company's cash position, how the follow-on public offering impacted its capital, and its projected cash runway. Management outlines its strategy for funding operations, including potential future capital raises, and its ability to meet short-term and long-term financial obligations.
• Operational Progress: Management highlights significant milestones achieved in 2025, especially the progress of the BROADWAY and BROOKLYN trials, and strategic planning for regulatory submissions and commercialization. They discuss how these achievements impact the company's financial outlook and future prospects.

5. Financial Health and Liquidity:

The company's financial health, typical for a clinical-stage biopharmaceutical company, primarily depends on its cash position and funding strategy.

• Cash Position: The company maintained a strong cash position, ending 2025 with an estimated $350 million in cash and cash equivalents.
• Cash Runway: This cash position provides a projected cash runway into late 2027, based on current spending, meaning its existing capital should fund operations until then.
• Funding: In 2025, NewAmsterdam Pharma successfully completed a follow-on public offering, raising approximately $120 million in net proceeds. This funding will further clinical development and demonstrates the company's ability to access capital markets.
• Capital Resources: The company's primary capital resources are its cash and cash equivalents, plus its ability to raise additional capital through equity offerings, debt financing, or strategic collaborations. The 10-K discusses the company's capital allocation strategy and plans for securing future funding to support its extensive R&D pipeline and potential commercialization.

6. Future Outlook and Strategy:

NewAmsterdam Pharma's strategy centers on successfully developing and commercializing obicetrapib.

• Obicetrapib Clinical Trials: The company significantly advanced its pivotal Phase 3 clinical trial program for obicetrapib.
  • The BROADWAY trial, which studies obicetrapib alongside statins for patients with high cholesterol (dyslipidemia), expects to release initial results in mid-2026.
  • The BROOKLYN trial, focusing on patients with existing heart disease (atherosclerotic cardiovascular disease or ASCVD) and high "bad cholesterol" (LDL-C), expects to report initial results in late 2026.
  • These trials are crucial for demonstrating obicetrapib's effectiveness and safety, and will largely determine the company's near-term future.
• Regulatory Pathway: If Phase 3 results are successful, NewAmsterdam Pharma plans to submit a New Drug Application (NDA) to the U.S. FDA and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in the first half of 2027.
• Commercialization: The company actively prepares for potential commercialization. This includes evaluating market access strategies, building its commercial infrastructure, and engaging with key medical experts. They aim to address a significant unmet need for patients who cannot reach optimal LDL-C levels with current therapies.
• Long-Term Vision: The company's long-term vision includes exploring additional uses for obicetrapib and potentially expanding its pipeline through internal research or licensing new opportunities. However, the immediate focus remains on obicetrapib's primary indications.

7. Competitive Position:

The market for therapies that lower lipids, especially those reducing "bad cholesterol" (LDL-C) and heart disease risk, is highly competitive and rapidly changing.

• Existing Therapies: Statins, highly effective and widely used, dominate the market. Other established therapies include PCSK9 inhibitors (e.g., Repatha, Praluent), ezetimibe, and bempedoic acid. These treatments have proven safety and efficacy, and strong market presence.
• Emerging Competitors: Many pharmaceutical and biotech companies are developing new therapies for high cholesterol (dyslipidemia) and heart disease, including novel oral drugs, gene therapies, and RNA-based treatments.
• Obicetrapib's Differentiation: NewAmsterdam Pharma aims to position obicetrapib as a unique oral therapy that can significantly lower "bad cholesterol" (LDL-C) and potentially reduce serious heart-related problems (MACE). This is especially for patients who cannot reach optimal LDL-C levels with current standard treatments or who cannot tolerate statins. The company believes obicetrapib's unique mechanism (blocking CETP, which both lowers LDL-C and raises "good cholesterol" HDL-C) offers a strong value proposition. Its oral form also provides an advantage over injectable therapies.

Market & SEC Standing:

NewAmsterdam Pharma's shares trade on the Nasdaq under the ticker NAMS, and its warrants trade as NAMSW. As of June 30, 2025, the market value of its publicly traded shares (excluding insider holdings) was approximately $1.35 billion, with the stock trading around $18.11 per share. More recently, on February 5, 2026, the company had approximately 115 million shares outstanding.

The SEC recognizes the company as a "well-known seasoned issuer" and a "Large Accelerated Filer." This status reflects a history of timely and comprehensive reporting, providing greater flexibility in accessing capital markets and streamlining future SEC filings.

In Conclusion:

NewAmsterdam Pharma stands at a pivotal stage, with its lead candidate obicetrapib advancing through late-stage clinical trials. While the drug holds high potential to address a significant medical need, investors should recognize the substantial financial and operational risks inherent in a clinical-stage biopharmaceutical company. The upcoming Phase 3 data releases in 2026 will be critical milestones, shaping the company's future and its ability to secure regulatory approvals and successfully commercialize obicetrapib.